ReviewPediatric dermatology2025
Assessment of Alopecia Areata Disease Severity in Pediatric Patients.
Review in Pediatric dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alopecia areata: current concepts.Wiener klinische Wochenschrift · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Alopecia areata (AA) is an autoimmune disorder that causes nonscarring hair loss and significantly impacts quality of life, particularly in pediatric patients. Since the early 2000s, AA severity has been evaluated using the Severity of Alopecia Tool (SALT), which quantifies scalp hair loss. However, recent advancements in the assessment tools provide a more comprehensive evaluation of AA, which is important for both measuring improvement during clinical trials and for a more holistic assessment in routine care. This review examines the development and implementation of assessment tools for AA, including newer tools that incorporate findings beyond the scalp, psychosocial impact, and chronicity. Through these tools, clinicians can gain a more detailed understanding of the multifaceted impact of AA, leading to improved individualized treatment strategies and advancing research in pediatric dermatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.